Emergent BioSolutions | EBS - Ordinary Share Capital


Emergent BioSolutions reported $100K in Ordinary Share Capital for its fiscal quarter ending in June of 2023.





Ordinary Share Capital Change Date
Acadia Pharmaceuticals USD 169.18M 470K Dec/2025
Akebia Therapeutics USD 265.42M 199K Dec/2025
ALKERMES USD 165.61M 503K Dec/2025
Alnylam Pharmaceuticals USD 132.38M 585K Dec/2025
Amarin USD 20.81M 13K Dec/2025
ANI Pharmaceuticals USD 22.49M 760K Dec/2025
BioMarin Pharmaceutical USD 192.3M 201K Dec/2025
Coherus Biosciences USD 121.16M 4.92M Dec/2025
Emergent BioSolutions USD 100K 0 Jun/2023
Exelixis USD 268.1M 2.03M Sep/2025
Glaxosmithkline GBP 4.08B 49.43M Dec/2025
Heron Therapeutics USD 188.31M 4.99M Dec/2025
Ionis Pharmaceuticals USD 161.97M 836K Dec/2025
Ironwood Pharmaceuticals USD 160K 0 Dec/2024
Lexicon Pharmaceuticals USD 363.47M 67K Dec/2025
Lonza CHF 68.64M 0 Dec/2025
Merck USD 2.49B 15.79M Sep/2025
Moderna USD 391M 2M Sep/2025
Myriad Genetics USD 93.5M 400K Dec/2025
Nektar Therapeutics USD 20.38M 20.36M Dec/2025
Neurocrine Biosciences USD 100.1M 400K Dec/2025
Pacira USD 41.12M 1.85M Dec/2025
Pfizer USD 5.69B 1000K Sep/2025
PTC Therapeutics USD 81.47M 1.54M Dec/2025
Sarepta Therapeutics USD 104.96M 196K Dec/2025
United Therapeutics USD 43.64M 740K Dec/2025
Vanda Pharmaceuticals USD 58K 0 Dec/2024
Xoma USD 87K 1000 Jun/2024